EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study

Yuichi Saito iD, Atsushi Tanaka iD, Hisako Yoshida, Hitoshi Nakashima, Noriko Ban, Munehide Matsuhisa iD, Yoshio Kobayashi, Koichi Node, On Behalf Of The Prize Study Investigators

Nutrients · 2024

DOI: 10.3390/nu16142324 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Yuichi Saito und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba 260-0856, Japan. Hauptthemen laut MEDLINE: Febuxostat, Hyperuricemia, Xanthine Oxidase, Lipids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Teijin (Japan), Teijin Pharma, Ltd., Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although patients with hyperuricemia and gout often have dyslipidemia, the effects of febuxostat, a xanthine oxidase inhibitor, on their lipid profiles are unclear. Thus, we performed a sub-analysis of the randomized PRIZE study in which the effects of febuxostat on carotid atherosclerosis were investigated in patients with hyperuricemia. The participants were randomized to the febuxostat or control group. The primary endpoint of this sub-analysis was changes in the patients’ non-high-density lipoprotein cholesterol (HDL-C) levels from baseline to 6-month follow-up. Correlations between the changes in lipid profiles and cardiometabolic parameters were also evaluated. In total, 456 patients were included. From baseline to 6 months, non-HDL-C levels were significantly reduced in the febuxostat group (−5.9 mg/dL, 95% confidence interval [CI]: −9.1 to −2.8 mg/dL, p < 0.001), but not in the control group (−1.3 mg/dL, 95% CI: −4.4 to 1.8, p = 0.348). The reduction in non-HDL-C levels was more pronounced in women and correlated with changes in serum uric acid and estimated glomerular filtration rate levels only in the febuxostat group. In patients with hyperuricemia, febuxostat treatment was associated with reduced non-HDL-C levels from baseline to the 6-month follow-up compared to the control treatment, suggesting that the lipid-lowering effect of febuxostat should be considered when targeting dyslipidemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FebuxostatHyperuricemiaXanthine OxidaseLipidsHumansMaleFemaleMiddle AgedAgedUric AcidGout SuppressantsCholesterol, HDLCarotid Artery DiseasesDyslipidemiasGlomerular Filtration Rate

Stichwörter der Autor:innen

cholesteroldyslipidemiafebuxostathyperuricemia

Substanzen

FebuxostatXanthine OxidaseLipidsUric AcidGout SuppressantsCholesterol, HDL

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba 260-0856, Japan.
  • Department of Cardiovascular Medicine, Saga University, Saga 849-8501, Japan.
  • Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Department of Cardiovascular Medicine, Imamura General Hospital, Kagoshima 890-0064, Japan.
  • Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba 260-0852, Japan.
  • Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima 770-8503, Japan.

ORCID-Profile: Yuichi Saito, Atsushi Tanaka, Munehide Matsuhisa

Förderung

  • Teijin (Japan)
  • Teijin Pharma, Ltd., Japan

Zitieren

APA

Saito, Y., Tanaka, A., Yoshida, H., Nakashima, H., Ban, N., Matsuhisa, M., Kobayashi, Y., Node, K., & On Behalf Of The Prize Study Investigators (2024). Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study. Nutrients. https://doi.org/10.3390/nu16142324

Vancouver

Saito Y, Tanaka A, Yoshida H, Nakashima H, Ban N, Matsuhisa M, et al. Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study. Nutrients. 2024. doi:10.3390/nu16142324

BibTeX
@article{Saito2024,
  author = {Saito, Yuichi and Tanaka, Atsushi and Yoshida, Hisako and Nakashima, Hitoshi and Ban, Noriko and Matsuhisa, Munehide and Kobayashi, Yoshio and Node, Koichi and On Behalf Of The Prize Study Investigators},
  title = {Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16142324}
}
Kostenlos starten →